Datos de interés

• Warner Chilcott Announces Decision in Doryx Patent Litigation - MarketWatch (press release)
  

  New York TimesWarner Chilcott Announces Decision in Doryx Patent LitigationMarketWatch (press release)DUBLIN, Ireland, Apr 30, 2012 (GlobeNewswire via COMTEX) -- Warner Chilcott plc (NASDAQ:WCRX) today announced that the US District Court for the District of New Jersey upheld the validity of the US patent covering the Company's DORYX 150 mg product .

• Warner Chilcott confirma que busca posibles compradores - El Global
  

  Warner Chilcott confirma que busca posibles compradoresEl GlobalEn este sentido, ahora mismo, el más interesante sería Asacol, con unas ventas anuales de 800 millones de dólares, ya que el laboratorio irlandés ha perdido recientemente la exclusividad para los productos Actonel y Doryx.

• Mylan Launches First Generic Version of Doryx® 150 mg - MarketWatch (press release)
  

  Mylan Launches First Generic Version of Doryx® 150 mgMarketWatch (press release)Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx® 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

• Teva settles Nuvigil patent litigation with Mylan, which debuts generic Doryx - The Pharma Letter
  

  New York TimesTeva settles Nuvigil patent litigation with Mylan, which debuts generic DoryxThe Pharma LetterThe antibiotic product is the generic version of Mayne Pharma's Doryx, marketed by Warner Chilcott in the USA, and is a tetracycline-class antimicrobial.

• Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2012 - MarketWatch (press release)
  

  Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2012MarketWatch (press release)Net sales of DORYX in the quarter ended March 31, 2012 were $30 million, a decrease of $36 million, or 55%, compared to the prior year quarter.